Preclinical and clinical development of ABTL0812: a new antitumoral drug that induces autophagy-mediated cancer cell death by upregulating TRIB3 pseudokinase and impairing of Akt/mTORC1 axis.

Publications

Preclinical and clinical development of ABTL0812: a new antitumoral drug that induces autophagy-mediated cancer cell death by upregulating TRIB3 pseudokinase and impairing of Akt/mTORC1 axis.

P. Muñoz-Guardiola, E. Megías-Roda, T. Erazo, H. Pérez, S. Solé-Sánchez, N. Diéguez, M. Yeste, M. Cortal, G. Velasco, J. Alfon, C. Domènech, J.M. Lizcano.

1st Oncobell Symposium. Mechanisms of Cancer and New Therapeutic Strategies. Barcelona 2018.

LATEST NEWS

11.05.2021

Press Release

Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as First Line Therapy in Advanced Pancreatic Cancer simultaneously in USA and Europe + info

28.12.2020

Press Release

The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info

16.12.2020

Press Release

The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info

05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info

22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info

22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info

09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info

25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info

12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info